Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway. (Q55223095)
Jump to navigation
Jump to search
scientific article published on 11 May 2018
Language | Label | Description | Also known as |
---|---|---|---|
English | Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway. |
scientific article published on 11 May 2018 |
Statements
Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway (English)
Chao Yu
Shiyu Chen
Yuntao Guo